⚛️ biophysics

Functional Screening of Kv7.5 Channel Variants Associated with Neuronal Dysfunction

This study presents the first automated patch-clamp functional screen of heterozygous Kv7.5/Kv7.3 channel variants, categorizing them into gain-of-function, loss-of-function, and neutral groups based on altered voltage dependence or current density, while proposing a z-score classification system and highlighting the potential for targeted pharmacogenetic therapies using XE991.

Original authors: Hunter, D. V., Vishwakarma, S., Givzad, N., Liu, J., Sanei, M., Kersey, B., Klein Geltink, R. I., Poburko, D. T., Prondzynski, M., Claydon, T.

Published 2026-11-04

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Hunter, D. V., Vishwakarma, S., Givzad, N., Liu, J., Sanei, M., Kersey, B., Klein Geltink, R. I., Poburko, D. T., Prondzynski, M., Claydon, T.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The human brain relies on a delicate balance of electrical signals to think, move, and feel. These signals are generated by tiny gates embedded in the surface of nerve cells, known as ion channels. Among these, a specific family of gates called Kv7 channels acts like a brake, slowing down electrical activity to prevent the brain from becoming overexcited. When these brakes work correctly, they allow for steady, controlled firing of neurons. However, when the genes that build these channels carry errors, the brakes can fail or become too sensitive, leading to neurological conditions such as epilepsy and developmental delays. One specific member of this family, the Kv7.5 channel, is less understood than its relatives, yet recent genetic testing has begun to uncover a variety of errors in its code. The critical challenge for doctors and scientists has been determining which of these genetic errors are harmless and which are dangerous, a distinction that is essential for guiding patient care.

A team of researchers at Simon Fraser University and the University of British Columbia set out to solve this puzzle by building a high-speed testing system to see how these genetic errors actually affect the function of the Kv7.5 channel. Instead of testing one channel at a time with a single glass probe, a method that is slow and labor-intensive, they utilized an automated platform capable of measuring hundreds of cells simultaneously. They created a library of cells, each engineered to carry one of nine different genetic variants found in patients. To ensure these channels behaved as they would in the human body, the researchers coaxed the cells to produce a partner protein that helps the Kv7.5 channel travel to the cell surface and function properly. They then applied a precise voltage to each cell to open the gates and measured the resulting electrical current, looking for signs that the channel was either too weak to stop overexcitation or too strong and active.

The results revealed a clear split in how these genetic errors behave. Some variants acted as a loss of function, producing significantly less electrical current than normal, which would likely leave neurons too excitable. Others acted as a gain of function, producing more current than usual or opening their gates at the wrong time, which could disrupt the normal rhythm of brain activity. Specifically, the researchers found that variants labeled G347S and P369R made the channels work harder and open more easily, while variants like V145G and W303C made them work less effectively. Interestingly, a few other variants showed no significant change in function, suggesting they might be harmless. To make sense of these varied results, the team developed a new scoring system that compares the behavior of each variant against the average behavior of normal channels. This system allows them to categorize the variants based on how far they deviate from the norm, providing a quantitative way to judge their potential danger.

Beyond simply classifying the errors, the study explored whether these malfunctioning channels could be targeted with drugs. The researchers tested a compound known to block Kv7 channels and found that the variants causing excessive activity were actually more sensitive to this blocker than normal channels. This suggests that for patients with these specific gain-of-function errors, a targeted drug could potentially restore balance by dampening the overactive channels. While the researchers noted that their current testing method has limitations and that more data is needed to refine their scoring system, this work provides the first large-scale, automated look at how Kv7.5 variants function. By turning genetic codes into measurable electrical behaviors, the study offers a new roadmap for understanding the root causes of neurological disorders and points toward more personalized treatments in the future.

Technical Summary: Functional Screening of Kv7.5 Channel Variants Associated with Neuronal Dysfunction

Problem Statement
The KCNQ5 gene encodes Kv7.5 potassium channels, which, alongside Kv7.2 and Kv7.3, contribute to the neuronal M-current critical for regulating excitability. While genetic variants in KCNQ5 have been linked to neurological disorders such as developmental encephalopathy and epilepsy, a causal link between specific variants and pathogenicity is often lacking. The absence of functional characterization limits clinical decision-making and the assignment of pathogenic risk for variants of uncertain significance. Furthermore, existing high-throughput screening methods for ion channels have not been fully established for Kv7.5, particularly in the context of heterozygous expression and heteromultimeric assembly with Kv7.3.

Methodology
The authors established a high-content automated patch clamp screen to functionally characterize a panel of nine heterozygous Kv7.5 variants (A131V, V145G, W303C, G347S, R359H, P369R, R491H, R497C, and L341I).

Cell Line Construction: The study utilized Flp-In T-REx 293 cells stably integrated with bicistronic constructs containing wild-type (WT) or variant KCNQ5 cDNA. To mimic the physiological heterozygous state and facilitate surface expression, cells were transiently transfected with WT KCNQ3.
Optimization of Recording Conditions: Initial recordings at 37°C showed unanticipated current rundown. The authors optimized conditions by lowering the recording temperature to 25°C, reducing intracellular fluoride concentration (from 110 mM to 40 mM KF), supplementing the internal solution with 1 µM diC8-PIP2 and 2.5 mM CaCl2, and ensuring co-expression of Kv7.3. These modifications stabilized channel function and minimized rundown.
Electrophysiology: Experiments were conducted using the SyncroPatch 384 automated planar patch clamp platform. Protocols included voltage steps from -110 mV to +40 mV to measure current density, activation kinetics, and voltage-dependence of activation ( $V_{1/2}$ ).
Pharmacology: The Kv7 channel blocker XE991 (1 µM and 30 µM) was applied to assess channel sensitivity and block mechanisms.
Data Analysis: Current density was normalized to cell capacitance. A z-score-based classification system was implemented to quantify variant effects relative to the WT distribution. Z-scores were calculated for current density, $V_{1/2}$ , and activation time constants ( $\tau_{act}$ ). Variants falling outside the 95% confidence interval of the WT data were considered significantly different.

Key Results
The screen identified distinct functional phenotypes among the nine variants:

Gain-of-Function (GOF): Variants G347S, P369R, and R497C exhibited increased current density. Additionally, L341I, G347S, and P369R showed a significant left-shift in the voltage-dependence of activation ( $V_{1/2}$ ), indicating channels open at more hyperpolarized potentials. L341I, G347S, and P369R also displayed slower activation kinetics. The authors note that L341I, G347S, and P369R channels did not close even at strongly hyperpolarized voltages, suggesting constitutive activation.
Loss-of-Function (LOF): Variants V145G and W303C demonstrated reduced current density (approximately 60% of WT) without significant changes in gating properties, consistent with reduced channel expression or trafficking.
No Apparent Effect: Variants A131V, R359H, and R491H showed no significant deviation from WT in current density or biophysical properties.
Drug Sensitivity: The GOF variants (L341I, G347S, P369R) showed increased sensitivity to block by 1 µM XE991 compared to WT, consistent with an open-channel block mechanism. The LOF variant V145G also showed altered sensitivity, potentially due to allosteric modification of the binding site.

Significance and Claims
The paper claims to present the first automated patch clamp functional screen of heterozygous Kv7.5/Kv7.3 channel variants. The study's primary contributions include:

Methodological Advancement: The establishment of optimized recording conditions (co-expression with Kv7.3, PIP2 supplementation, reduced fluoride) that enable robust, reproducible Kv7.5 functional screening in a high-throughput format.
Functional Characterization: The identification of specific gain-of-function and loss-of-function mechanisms for previously uncharacterized or uncertain variants, distinguishing between effects on current density and biophysical gating.
Pathogenicity Index: The initiation of a z-score-based classification system to guide the understanding of Kv7.5 variant pathogenicity. The authors acknowledge that while this system provides a quantitative framework, it currently lacks the breadth of benign controls found in other channelopathies (like hERG or Nav1.5) and requires refinement as more variants are characterized.
Pharmacogenetic Potential: The observation that GOF variants exhibit heightened sensitivity to XE991 suggests a potential, albeit challenging, avenue for targeted pharmacogenetic approaches to restore normal channel function.

The authors maintain a modest tone regarding the z-score system, noting that the current range is limited by the variability of the WT dataset and the lack of a large benign control cohort. They emphasize that future work involving broader variant datasets and clinical correlations is necessary to refine the index for clinical utility.

More like this